首页> Circulation> Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.

Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.

导出 OA

翻译打印收藏纠错

第一作者： Mikhail N,Kosiborod

第一单位： Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City (M.N.K.).;The George Institute for Global Health and University of New South Wales, Sydney, Australia (M.N.K).

作者： Mikhail N,Kosiborod ^[1] ; Pardeep S,Jhund ^[2] ; Kieran F,Docherty ^[2] ; Mirta,Diez ^[3] ; Mark C,Petrie ^[2] ; Subodh,Verma ^[4] ; Jose C,Nicolau ^[5] ; Béla,Merkely ^[6] ; Masafumi,Kitakaze ^[7] ; David L,DeMets ^[8] ; Silvio E,Inzucchi ^[9] ; Lars,Køber ^[10] ; Felipe A,Martinez ^[11] ; Piotr,Ponikowski ^[12] ; Marc S,Sabatine ^[13] ; Scott D,Solomon ^[13] ; Olof,Bengtsson ^[14] ; Daniel,Lindholm ^[14] ; Anna,Niklasson ^[14] ; Mikaela,Sjöstrand ^[14] ; Anna Maria,Langkilde ^[14] ; John J V,McMurray ^[2]

作者单位： Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City (M.N.K.).;The George Institute for Global Health and University of New South Wales, Sydney, Australia (M.N.K). ^[1] British Heart Foundation Cardiovascular Research Centre, University of Glasgow, UK (P.S.J., K.F.D., M.C.P., J.J.V.M.). ^[2] Division of Cardiology, Instituto Cardiovascular de Buenos Aires, Argentina (M.D.). ^[3] St Michael's Hospital, University of Toronto, Canada (S.V.). ^[4] Instituto do Coracao (InCor), Hospital das Clínicas Faculdade de Medicina, Universidade de São Paulo, Brazil (J.C.N.). ^[5] Heart and Vascular Center, Semmelweis University, Budapest, Hungary (B.M.). ^[6] Department of Clinical Medicine and Development, National Cerebral and Cardiovascular Center, Suita Osaka, Japan (M.K.). ^[7] Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison (D.L.D.). ^[8] Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.). ^[9] Rigshospitalet, Department of Cardiology, University of Copenhagen, Denmark (L.K.). ^[10] Universidad Nacional de Córdoba, Argentina (F.A.M.). ^[11] Center for Heart Diseases, University Hospital, Wroclaw Medical University, Poland (P.P.). ^[12] Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (M.S.S., S.D.S.). ^[13] Late Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (O.B., D.L., A.N., M.S., A.M.L.). ^[14]

关键词 health status heart failure outcome sodium-glucose transporter 2 inhibitors